Palatin Technologies (PTNT) AI Stock Analysis

• Market Cap: $6.69M
• Dividend Yield: N/A
• Average Volume (3M): 599.81K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.91
• Revenue Growth: -94.07%
• EPS Growth: 52.36%
• Country: US
• Employees: 30
• Sector: Healthcare
• Sector Strength: 50
• Industry: Biotechnology
• EPS (TTM): -9.00
• Shares Outstanding: 929,597
• 10 Day Avg. Volume: 820,931
• 30 Day Avg. Volume: 599,811
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.96
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $7.00
• Price Target Upside: 4017.65% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 46 Neutral
• Price Target: $0.00 ▼(-100.00% Downside)

Palatin Technologies' overall score is heavily impacted by its poor financial performance and the negative corporate event of potential delisting. While some technical indicators suggest short-term bullish momentum, the overall bearish trend and unfavorable valuation metrics underscore significant risks. The company must address its financial instability to improve its market position.

Positive Factors

Clinical Trials

The completion of the Phase 2 BMT-801 clinical trial is a significant milestone for Palatin as it focuses on the obesity space, which is seen as a key driver of the company's long-term success.

Market Opportunities

Positive results from the Phase 2 study could validate the potential synergy between bremelanotide and GLP-1 receptor agonists, giving Palatin a foothold in the obesity treatment space.

Negative Factors

Funding Challenges

Factors that could impede reaching the price target include failed or inconclusive clinical trials or the inability to secure adequate funding for drug development.

Palatin Technologies Business Overview & Revenue Model

Company Description

Palatin Technologies, Inc. is a biopharmaceutical company focused on developing targeted receptor-specific therapeutics for the treatment of various medical conditions. The company primarily operates in the biotechnology sector, with a strong emphasis on developing treatments for inflammatory diseases and disorders related to sexual dysfunction. Palatin's core product includes Vyleesi, a melanocortin receptor agonist indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD).

How the Company Makes Money

Palatin Technologies generates revenue through the commercialization of its pharmaceutical products, primarily Vyleesi. Revenue streams include product sales, licensing agreements, royalties, and milestone payments from strategic partnerships and collaborations with other pharmaceutical companies. The company has established partnerships for the distribution and marketing of Vyleesi in various regions, which contributes to its earnings. Additionally, Palatin may receive government grants or funding for its research and development initiatives, although these are not primary revenue sources.

Palatin Technologies Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Palatin Technologies Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.17
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PTNT, the sentiment is Negative. The current price of 0.17 is below the 20-day moving average (MA) of 9.69, below the 50-day MA of 7.90, and below the 200-day MA of 30.04, indicating a bearish trend. The MACD of -0.59 indicates Positive momentum. The RSI at 40.76 is Neutral, neither overbought nor oversold. The STOCH value of 6.27 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PTNT.

Palatin Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BOLT	52 Neutral	$9.89M	―	-81.33%	―	-62.68%	23.94%
Sector *	51 Neutral	$7.70B	-0.29	-46.01%	2.24%	23.07%	-0.65%
ADXN	49 Neutral	$12.39M	0.69	-162.42%	―	-82.24%	―
BRTX	48 Neutral	$12.13M	―	-137.09%	―	247.62%	-7.66%
PTNT	46 Neutral	$6.69M	―		―	-94.07%	52.36%
IBIO	42 Neutral	$12.02M	―	-90.83%	―	650.00%	85.42%
PHIO	42 Neutral	$12.48M	―	-102.18%	―	―	85.26%

Palatin Technologies Corporate Events

Palatin Technologies Stockholders Approve Key Governance Changes

On July 25, 2025, Palatin Technologies held its annual meeting of stockholders to vote on several key issues, including the election of directors and an amendment to effect a reverse stock split. The stockholders approved the election of four directors and ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending June 30, 2025. Additionally, they approved the issuance of shares upon the exercise of certain stock purchase warrants and an amendment to increase the number of shares available for equity awards. These decisions are expected to impact the company’s financial structure and governance, potentially affecting its market positioning and stakeholder interests.

The most recent analyst rating on (PTNT) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Palatin Technologies stock, see the PTNT Stock Forecast page.

Palatin Technologies Faces NYSE Delisting Proceedings

On July 7, 2025, Palatin Technologies received a notification from NYSE American LLC regarding the initiation of delisting proceedings for the company’s common stock. A hearing was held on June 18, 2025, and the decision to delist was affirmed by a Listing Qualifications Panel. Palatin Technologies plans to appeal this decision and is working to address the listing deficiencies before the full Committee for Review, expected in late August or September 2025.

The most recent analyst rating on (PTNT) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Palatin Technologies stock, see the PTNT Stock Forecast page.

Palatin Technologies Raises $340K in Private Placement

On June 10, 2025, Palatin Technologies entered into a securities purchase agreement with accredited investors to sell Series D Convertible Preferred Stock and Series I common stock purchase warrants in a private placement, closing on June 13, 2025, raising $340,000 for working capital. The Preferred Stock, convertible into common stock, and warrants were sold at $0.11 per share, with key company executives participating as purchasers. The company plans to file a registration statement for resale of shares and warrants, impacting its financial strategy and shareholder structure.

The most recent analyst rating on (PTNT) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Palatin Technologies stock, see the PTNT Stock Forecast page.